Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Opdivo“
Suchtreffer
Begriffe & Kennungen
Opdivo · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenOpdivo · 4.8 Undesirable effects · 1
Eintrag öffnenOpdivo · 4.8 Undesirable effects · 2
Eintrag öffnenOpdivo · 4.8 · 163 uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); not known (cannot
Eintrag öffnenOpdivo · 4.8 · 164 Nivolumab monotherapy Respiratory, thoracic and mediastinal disorders Very common dyspnoeaa, cough Common
Eintrag öffnenOpdivo · 4.8 · 165 l Oedema is a composite term which includes generalised oedema, oedema peripheral, peripheral swelling and
Eintrag öffnenOpdivo · 4.8 · 166 (10.0%). The incidence of Grade 3-5 adverse reactions was 78%, with 0.3% fatal adverse reactions attribute
Eintrag öffnenOpdivo · 4.8 · 167 Combination with Combination with Combination with ipilimumab (with or chemotherapy cabozantinib without c
Eintrag öffnenOpdivo · 4.8 · 168 Combination with Combination with Combination with ipilimumab (with or chemotherapy cabozantinib without c
Eintrag öffnenOpdivo · 4.8 · 169 Combination with Combination with Combination with ipilimumab (with or chemotherapy cabozantinib without c
Eintrag öffnenOpdivo · 4.8 · 170 Combination with Combination with Combination with ipilimumab (with or chemotherapy cabozantinib without c
Eintrag öffnenOpdivo · 4.8 · 171 Table 14: Immune-related adverse reactions leading to permanent discontinuation or requiring high-dose cor
Eintrag öffnenOpdivo · 4.8 · 172 Resolution occurred in 58 patients (72.5%) with a median time to resolution of 10.4 weeks (range: 0.3+-171
Eintrag öffnenOpdivo · 4.8 · 173 In patients treated with nivolumab in combination with chemotherapy, the incidence of liver function test
Eintrag öffnenOpdivo · 4.8 · 174 (16/2626) and 0.5% (13/2626) of patients, respectively. Grade 2, Grade 3, and Grade 4 adrenal insufficienc
Eintrag öffnenOpdivo · 4.8 · 175 Infusion reactions (intravenous formulation) In patients treated with nivolumab monotherapy, the incidence
Eintrag öffnenOpdivo · 4.8 · 176 In patients treated with nivolumab in combination with chemotherapy, the proportion of patients who experi
Eintrag öffnenOpdivo · 4.8 · 177 ipilimumab and chemotherapy and evaluable for the presence of anti-ipilimumab antibodies or neutralising a
Eintrag öffnenOpdivo · 4.8 · 26 Nivolumab monotherapy Metabolism and nutrition disorders Very common decreased appetite, hyperglycaemiab Co
Eintrag öffnenOpdivo · 4.8 · 27 Nivolumab monotherapy Renal and urinary disorders Common renal failure (including acute kidney injury)a Rar
Eintrag öffnen